MethylGene (TSX: MYG) is a clinical-stage biopharmaceutical company that develops novel therapeutics for cancer and infectious disease.
Charles M. Baum, MD PhD, has been appointed Chief Executive Officer of MethylGene. News Release
MGCD265 targets the Met and VEGF kinases, which appear to play key roles in tumor development, blood vessel formation (angiogenesis) and tumor survival.
MethylGene announces plan to reincorporate in the United States as Mirati Therapeutics Inc. and list on NASDAQ. See news release.
May 13, 2013
METHYLGENE REPORTS FIRST QUARTER 2013 FINANCIAL RESULTS ...
May 9, 2013
METHYLGENE ANNOUNCES PLAN TO REINCORPORATE IN THE UNITED STATES AS MIRATI THERAPEUTICS, INC. AND ...
April 8, 2013
METHYLGENE PRESENTS PRECLINICAL DATA ON MG516 AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ...
May 31 - June 4, 2013, Chicago
2013 ASCO Annual Meeting
June 3-6, 2013, New York
Jefferies 2013 Global Healthcare Conference
June 25, 2013 at 10AM, Stikeman Elliott LLP, 1155 René-Lévesque Blvd. West, 40th Floor, Montreal
Annual and Special Meeting of Shareholders
